Changes in Hong Kong stocks | Jingfang Pharmaceutical-B (02595) rose more than 5% GFH276 pancreatic cancer combination therapy study completed the administration of the first patients enrolled in China and overseas

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Jingfang Pharmaceutical-B (02595) rose more than 5% in the intraday period. As of press release, it had risen 3.83% to HK$20.08, with a turnover of HK$10.9661 million.

According to the news, on November 16, Jingfang Pharmaceutical-B announced that the oral pan-RAS inhibitor GFH276 has entered a phase IB/II multi-center, open-label combination therapy study, which will be carried out at dozens of Chinese and Australian research centers. The first overseas enlisted patient recently completed administration at Monash Health in Australia. The first Chinese enrolled patient completed administration at Fudan University Cancer Hospital in the third quarter of this year.

According to this year's ESMO Annual Conference Breakthrough Research Summary (LBA), as of the data cutoff date, 72.6% of pancreatic duct adenocarcinoma (PDAC) patients received GFH276 as line 3 or above treatment, and no dose-limiting toxicity was observed at 40-160 mg QD dose levels (patients did not use prophylactic drugs); the overall objective response rate (ORR) of 61 PDAC patients (40-160 mg QD) who could evaluate efficacy was 41.1%. ORR was 43.1%.